Artelo biosciences announces positive first-in-human data for art26.12, a novel non-opioid treatment candidate for persistent pain

First orally active fatty acid binding protein 5 inhibitor evaluated in humans first-in-class approach targets unmet need in multibillion-dollar pain management market solana beach, calif., june 30, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating art26.12, a novel inhibitor of fatty acid binding protein 5 (fabp5).
ARTL Ratings Summary
ARTL Quant Ranking